CNSTライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary ():

Stats
本日の出来高	0
平均出来高	0
時価総額	0
EPS	$0 ( 2021-08-03 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Constellation 相関

10 最も正の相関
TLMD	0.947
MDWT	0.94
RMRM	0.926
ATOM	0.923
SVOK	0.923
MDXG	0.92
NNOX	0.918
WWD	0.918
LIXT	0.916
MEIP	0.915

10 最も負の相関
BOCH	-0.944
SMSI	-0.929
APTX	-0.92
TWKS	-0.917
UPLD	-0.913
MMAC	-0.905
NETE	-0.903
TTEC	-0.903
EYE	-0.901
INGN	-0.896

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Constellation 財務諸表

Annual	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-4.49

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-4.49

FY	2019
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-3.04

FY	2018
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-5.00

Financial Reports:

No articles found.

Constellation

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. The company is also developing CPI-0209 that is in Phase I dose escalation portion of a Phase I/II clinical trial to treat solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.